Egaptivon pegol
Term · Oncology and biomedicine · MLC-T-ONC-013234
An optimized, second-generation, PEGylated aptamer with antithrombotic property. Egaptivon pegol blocks the binding of von Willebrand factor (vWF), via the A1 domain, and ultra-large vWF multimers to platelets, as well as interferes with the binding of platelet receptor glycoprotein Ib, thus reducing platelet adhesion, aggregation and thrombus growth in arterial beds. Unlike other antiplatelet agents, this aptamer can be readily reversed by binding to a complementary sequence of oligonucleotides, and may therefore offer potential therapeutic benefit in surgery.
| Identifier | MLC-T-ONC-013234 |
|---|---|
| Field | Oncology and biomedicine |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-013234",
"term": "Egaptivon pegol",
"field": "Oncology and biomedicine",
"definition": "An optimized, second-generation, PEGylated aptamer with antithrombotic property. Egaptivon pegol blocks the binding of von Willebrand factor (vWF), via the A1 domain, and ultra-large vWF multimers to platelets, as well as interferes with the binding of platelet receptor glycoprotein Ib, thus reducing platelet adhesion, aggregation and thrombus growth in arterial beds. Unlike other antiplatelet agents, this aptamer can be readily reversed by binding to a complementary sequence of oligonucleotides, and may therefore offer potential therapeutic benefit in surgery.",
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/egaptivon-pegol/"
}
Record 6,418 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.